Topline results from a phase 2 clinical trial of an investigational gene therapy for Parkinson’s disease showed that high doses of the medication improved disease-specific and quality of life measures significantly by week 26. The trial investigated the safety and tolerability of the therapy in individuals with idiopathic PD, resulting in improvements in both high and low-dose cohorts compared to a sham group. The therapy was well-tolerated with no serious adverse events related to treatment reported. The company, MeiraGTx, reported positive outcomes from the trial, indicating that the gene therapy could be a promising treatment option for Parkinson’s disease.
Source link
High dose of novel PD gene therapy linked to improved outcomes at 26 weeks
